title: [Examination of continuity of S-1 adjuvant chemotherapy for gastric cancer patients after gastrectomy].
abstract: Next to ACTS-GC (Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer), adjuvant chemotherapy with S-1 is the standard treatment for stage II or III gastric cancer patients.In this study, we retrospectively examined the continuity and adverse reaction of S-1 adjuvant chemotherapy in 30 gastric cancer patients who visited our hospital from 2007 to 2008, and compared them with those of patients treated with ACTS-GC. Whereas the persistent rate of S-1 adjuvant chemotherapy for one year in ACTS-GC was 65.8%, it was 86.7% in our hospital.The RP (Relative performance) value in cases who completed S-1 adjuvant therapy for one year in ACTS-GC and for one year in our hospital was 81.2% and 88.5%, respectively. Grade 3/4 adverse events in our hospital were leukopenia (3.3%), neutropenia (16.7%), and anorexia(6.7%). In conclusion, our hospital has shown a far greater continuity with S- 1 adjuvant chemotherapy than with ACTS-GC, a result suggesting that S-1 adjuvant chemotherapy is feasible in clinical practice.
authors.affiliation: Dept. of Surgery, Sakai Municipal Hospital.
authors.forename: Ryohei
authors.initials: R
authors.lastname: Kawabata
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imamura
authors.forename: Tomono
authors.initials: T
authors.lastname: Kishimoto
authors.forename: Setsuko
authors.initials: S
authors.lastname: Anami
authors.forename: Yukako
authors.initials: Y
authors.lastname: Yasui
authors.forename: Misako
authors.initials: M
authors.lastname: Fujino
authors.forename: Chika
authors.initials: C
authors.lastname: Fujii
authors.forename: Rumi
authors.initials: R
authors.lastname: Sumida
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Furukawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D010348:Patient Care Team; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid